Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abacavir/dolutegravir/lamivudine - ViiV Healthcare

Next Previous
X
Search
Drug Profile

Abacavir/dolutegravir/lamivudine - ViiV Healthcare

Alternative Names: 572-Trii; Abacavir/GSK-1349572/lamivudine; Dolutegravir-Trii; Dolutegravir/abacavir/lamivudine; DTG/ABC/3TC; DTG/ABC/3TC FDC; GSK-1349572/abacavir/lamivudine; Lamivudine/abacavir/GSK-1349572; Triumeq; Triumeq PD

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Shionogi ViiV Healthcare LLC
  • Developer GSK; Shionogi ViiV Healthcare LLC; ViiV Healthcare
  • Class Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 04 Jan 2023 Preregistration for HIV infections (In adolescents, In adults, In children) in European Union (PO) (3745769; 9377359)
  • 16 Dec 2022 Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion of HIV-infection in European union (3743358; 9377359)
  • 25 Sep 2022 Pharmacokinetics data from a phase I trial in HIV infections presented at the 2022 American College of Clinical Pharmacology Annual Meeting (ACCP-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top